Trastuzumab Deruxtecan vs Trastuzumab pamirtecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HER2-Positive Breast Cancer
Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline
Trastuzumab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT03523585 · Phase 3 · completed
The 608-participant trial was randomized and actively controlled, with progression-free survival assessed by blinded independent central review as the primary clinical endpoint. The primary comparison was statistically significant in favor of trastuzumab deruxtecan, but treatment assignment was open-label rather than double-blinded, supporting a moderate evidence grade.
Next expected readout: January 2027 · NCT06797622 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) (met)
Result source: NCT03523585
Trastuzumab pamirtecan
Developed by BioNTech under a licence from DualityBio Inc.
NCT06265428 · Phase 3 · active, not recruiting
Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2027 · NCT06265428 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Up to approximately 24 months.): NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. (met)
Result source: NCT06265428
Results for HER2-Positive Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Trastuzumab Deruxtecan
show 1 more result
show 1 more result
show 2 more results
show 4 more results
Available safety results
Trastuzumab Deruxtecan
| Dropout rate | 76.8% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results62.5%Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence 70%Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence 88.9%Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence 33.3%Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence 71.4%Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 18.2% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results—Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 25.5% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results0%Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence 10%Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence 55.6%Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence 16.7%Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence 57.1%Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | nausea 72.3% alopecia 37.1% vomiting 37.1% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more resultsfatigue 75% constipation 62.5% nausea 50% NCT04420598 · Phase 2 · registry result, not featured evidence fatigue 90% nausea 70% aspartate aminotransferase increased 50% NCT04420598 · Phase 2 · registry result, not featured evidence anaemia 44.4% fatigue 44.4% neutropenia 44.4% NCT04420598 · Phase 2 · registry result, not featured evidence nausea 57.1% anaemia 42.9% fatigue 42.9% NCT04420598 · Phase 2 · registry result, not featured evidence |
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Trastuzumab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT04494425 · Phase 3 · active, not recruiting
The trial was large and randomized, with an active chemotherapy comparator and a hard clinical primary endpoint of progression-free survival, which was met: median PFS was 13.2 versus 8.1 months, with HR 0.62 and p<0.0001. However, treatment assignment was not blinded, so despite the strong randomized result this is considered moderate evidence rather than strong evidence.
Next expected readout: November 2026 · NCT06048718 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) (met)
Result source: NCT04494425
Trastuzumab pamirtecan
Developed by BioNTech under a licence from DualityBio Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2029 · NCT06827236 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Trastuzumab Deruxtecan | Trastuzumab pamirtecan |
|---|---|---|
| PFS, median | —Trial running · NCT04494425 | —Trial running · NCT06018337 |
| OS, median | —Trial running · NCT04494425 | —Trial running · NCT06018337 |
| ORR | —Trial running · NCT04494425 | —Trial running · NCT06018337 |
| Clinical benefit rate | —Trial running · NCT04494425 | —Trial running · NCT06018337 |
PFS, median
- Trastuzumab Deruxtecan
- —Trial running · NCT04494425
- Trastuzumab pamirtecan
- —Trial running · NCT06018337
OS, median
- Trastuzumab Deruxtecan
- —Trial running · NCT04494425
- Trastuzumab pamirtecan
- —Trial running · NCT06018337
ORR
- Trastuzumab Deruxtecan
- —Trial running · NCT04494425
- Trastuzumab pamirtecan
- —Trial running · NCT06018337
Clinical benefit rate
- Trastuzumab Deruxtecan
- —Trial running · NCT04494425
- Trastuzumab pamirtecan
- —Trial running · NCT06018337
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Trastuzumab pamirtecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Trastuzumab Deruxtecan's landscape · Trastuzumab pamirtecan's landscape